Glibenclamide (Daonil) tab 5 mg discontinuation
The supplier, Sanofi, is discontinuing Daonil (glibenclamide) tab 5 mg globally.
Affected product
Daonil was first approved for use in New Zealand in 1969. It has been largely superseded by newer medicines to treat type 2 diabetes.
The supplier expects stock Daonil to run out in February 2027.
- Chemical: Glibenclamide
- Presentation: Tab 5 mg
- Brand: Daonil
- Pharmacode: 203106
- Subsidy: $7.50
- Measure / Qty: per 100
People who take Daonil
Please talk to the person who prescribes your medicine before February 2027. They will be able to discuss the best approach to help manage your diabetes.
We are aware that there is a small group of people who cannot change from glibenclamide, because it is the best treatment for their specific type of diabetes.
Your prescriber can apply to Pharmac to get this medicine funded for you specifically. This process is called the Named Patient Pharmaceutical Assessment (NPPA). Please talk to your prescriber about this option if it is relevant.
Health care professionals
Please talk to anyone you prescribe glibenclamide for before February 2027. If they are to continue receiving funded treatment, you will need to prescribe a different medicine or apply for individual funding.
There may be a small number of people that cannot move to other treatment. Please consider applying for a Named Patient Pharmaceutical Assessment (NPPA) so your patient can continue to access funded glibenclamide.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)